SSA
RCKT icon

Schonfeld Strategic Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

Schonfeld Strategic Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-149,413
Closed -$524K – 2590
2025
Q4 		$524K Buy
+149,413
New +$512K ﹤0.01% 1376
2025
Q3 		– Sell
-28,362
Closed -$69.5K – 2506
2025
Q2 		$69.5K Buy
28,362
+16,930
+148% +$85.8K ﹤0.01% 1863
2025
Q1 		$76.3K Buy
+11,432
New +$113K ﹤0.01% 2043
2023
Q4 		– Sell
-10,400
Closed -$213K – 2160
2023
Q3 		$213K Sell
10,400
-19,724
-65% -$359K ﹤0.01% 1402
2023
Q2 		$599K Buy
+30,124
New +$609K 0.01% 1150
2023
Q1 		– Sell
-51,024
Closed -$999K – 2541
2022
Q4 		$999K Sell
51,024
-22,488
-31% -$414K 0.01% 1152
2022
Q3 		$1.17M Buy
+73,512
New +$1.15M 0.01% 1165
2022
Q1 		– Sell
-41,400
Closed -$903K – 2866
2021
Q4 		$903K Sell
41,400
-29,870
-42% -$815K 0.01% 988
2021
Q3 		$2.13M Buy
71,270
+35,067
+97% +$1.28M 0.02% 691
2021
Q2 		$1.6M Sell
36,203
-298
-0.8% -$12.9K 0.02% 787
2021
Q1 		$1.62M Sell
36,501
-3,111
-8% -$171K 0.02% 728
2020
Q4 		$2.17M Buy
39,612
+13,591
+52% +$495K 0.03% 580
2020
Q3 		$595K Sell
26,021
-24,934
-49% -$614K 0.01% 860
2020
Q2 		$1.07M Buy
+50,955
New +$919K 0.03% 587
2020
Q1 		– Sell
-36,435
Closed -$829K – 1453
2019
Q4 		$829K Sell
36,435
-39,165
-52% -$654K 0.02% 562
2019
Q3 		$881K Sell
75,600
-107,300
-59% -$1.33M 0.03% 503
2019
Q2 		$2.74M Buy
182,900
+158,300
+643% +$2.76M 0.1% 240
2019
Q1 		$432K Sell
24,600
-77,600
-76% -$1.23M 0.02% 734
2018
Q4 		$1.51M Buy
102,200
+77,200
+309% +$1.28M 0.06% 378
2018
Q3 		$616K Buy
+25,000
New +$542K 0.03% 535
2018
Q2 		– Sell
-24,460
Closed -$459K – 929
2018
Q1 		$459K Buy
+24,460
New +$399K 0.03% 496

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Schonfeld Strategic Advisors's RCKT Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of Rocket Pharmaceuticals (RCKT) in Q1 2026, closing a stake of 149,413 shares — an estimated $524K sold.

Schonfeld Strategic Advisors first reported a position in RCKT in Q1 2018 and held it in 21 quarters. The position peaked at $2.74M in Q2 2019. 198 funds tracked by Wall St. Rank hold RCKT as of Q1 2026.

  • Schonfeld Strategic Advisors reported no remaining Rocket Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 149,413 Rocket Pharmaceuticals shares in Q1 2026, an estimated $524K.
  • Schonfeld Strategic Advisors first reported a position in Rocket Pharmaceuticals in Q1 2018 and held it in 21 quarters.
  • Schonfeld Strategic Advisors's Rocket Pharmaceuticals position peaked at $2.74M in Q2 2019.
  • 198 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.